• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S ADR (NY: NVO )

    124.39 -2.56 (-2.02%)
    Streaming Delayed Price Updated: 3:56 PM EDT, Sep 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,942,492
    Open 125.60
    Bid (Size) 124.38 (2)
    Ask (Size) 124.39 (1)
    Prev. Close 126.95
    Today's Range 123.98 - 125.62
    52wk Range 86.96 - 148.15
    Shares Outstanding N/A
    Dividend Yield 1.42%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
    Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization. 
    Via Benzinga
    Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
    Even the mighty Novo Nordisk can't hold a candle to its peer in this area. 
    Via The Motley Fool

    Performance

    YTD
    +21.82%
    +21.82%
    1 Month
    -8.06%
    -8.06%
    3 Month
    -13.42%
    -13.42%
    6 Month
    -2.86%
    -2.86%
    1 Year
    +35.52%
    +35.52%

    More News

    Read More
    EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
    Via Benzinga
    Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
    Via The Motley Fool
    Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
    Via Benzinga
    Novo Nordisk's Options: A Look at What the Big Money is Thinking
    Via Benzinga
    Novo Nordisk's Options: A Look at What the Big Money is Thinking
    Via Benzinga
    Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
    Via Benzinga
    Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
    Via Benzinga
    Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
    Via Benzinga
    Exposures Product Safety
    EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
    Via Benzinga
    Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
    Via Benzinga
    Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
    Via MarketBeat
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
    From Aligos Therapeutics
    Via GlobeNewswire
    'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
    Via Benzinga
    2 Weight-Loss Stocks That Could Rocket Higher This Year
    Via The Motley Fool
    Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
    Via Benzinga
    Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
    Via Benzinga
    Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
    Via Benzinga
    Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
    Via Benzinga
    3 Stocks That Could Rise on European Bank Interest Rate Cuts
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
    Via Investor's Business Daily
    Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
    Via The Motley Fool
    US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.